Impact of early blood purification on serum inflammatory mediators and hemorheology in severe acute pancreatitis

早期血液净化对重症急性胰腺炎患者血清炎症介质和血液流变学的影响

阅读:1

Abstract

BACKGROUND: Patients with severe acute pancreatitis (SAP) often experience systemic inflammatory responses and microcirculatory disturbances, for which existing treatments have limited intervention effects. OBJECTIVES: It aimed to investigate the impact of early blood purification on serum inflammatory mediators, hemorheological parameters, and clinical prognosis in patients with SAP. METHODS: 120 patients with SAP were randomly grouped: observation group (OG) (routine treatment + early continuous veno-venous hemodiafiltration) and control group (CG) (routine treatment). The time to clinical symptom improvement, hemorheological parameters [whole blood viscosity (WBV), plasma viscosity (PV), hematocrit, and platelet adhesion rate], and inflammatory mediators were compared. Multivariate logistic regression analysis (MLRA) was used to identify prognostic factors. RESULTS: The OG had markedly shorter times to symptom relief for fever, abdominal pain, and abdominal distension (all P < 0.001) and a higher cure rate (P = 0.012); The levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), as well as WBV and PV, were more markedly improved (all P < 0.01). Multivariate analysis suggested that peak CRP (OR = 1.01, P < 0.001) and peak TNF-α (OR = 1.02, P = 0.003) maintained independent predictive value, and all hemorheological parameters were confirmed as independent prognostic factors. CONCLUSION: Early blood purification can effectively improve the inflammatory response and hemodynamics in patients with SAP, with its efficacy influenced by multiple factors, including disease severity, intensity of inflammatory response, and hemorheological status. CLINICAL TRIAL NUMBER: Not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。